Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its glucose monitoring products, the G6 and G7, which could pose health risks to users [1]. Group 1: Allegations - The complaint alleges that DexCom made unauthorized design changes to the G6 and G7 glucose monitoring products, which rendered them less reliable than previous versions [1]. - It is claimed that these design changes presented a material health risk to users who depend on these devices for accurate glucose readings [1]. - The enhancements to the G7's reliability, accuracy, and functionality were allegedly overstated by the defendants [1]. - The true scope and severity of the issues related to the G7 devices were reportedly downplayed by the defendants [1]. - The allegations suggest that DexCom faced increased regulatory scrutiny and potential legal, reputational, and financial harm due to these issues [1]. - As a result, the public statements made by the defendants were materially false and misleading throughout the relevant period [1]. Group 2: Class Action Details - Shareholders who purchased shares of DXCM during the class period from January 8, 2024, to September 17, 2025, are encouraged to register for the class action [2]. - The deadline for shareholders to seek lead plaintiff status is December 26, 2025, and there is no cost or obligation to participate in the case [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates on the case's status [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that led to artificial inflation of a company's stock [3].

Core Insights - DexCom, Inc. has launched Dexcom Academy, a personalized learning platform for healthcare professionals (HCPs) focused on continuous glucose monitoring (CGM) [1][2] - The platform aims to enhance HCP confidence in CGM use and improve diabetes care quality without increasing clinical burden [2][4] Group 1: Platform Features - Dexcom Academy offers both desktop and mobile app access, allowing HCPs to select learning resources that fit their needs through short, flexible modules [2][6] - The platform includes structured learning pathways, practical case studies, and certification courses to support professional development [6][7] - Educational resources are designed to be consultation-ready, enabling HCPs to apply their learning immediately in patient interactions [6][7] Group 2: HCP Feedback and Needs - Dexcom collaborated with HCPs to create a platform that addresses their needs for flexible, personalized, and practical education [3][5] - A survey indicated that 38% of HCPs believe ongoing education on diabetes technology is essential for overcoming challenges in patient care [4][9] - HCPs expressed a desire for training that is relevant and based on real case studies, which Dexcom Academy aims to provide [5][6] Group 3: Future Plans and Commitment - Dexcom plans to expand the availability of Dexcom Academy to more EMEA countries by 2026, demonstrating a long-term commitment to supporting diabetes care [1][8] - The initiative reflects Dexcom's investment in both product excellence and the education necessary for effective diabetes management [8][10]

Core Viewpoint - A securities fraud class action lawsuit has been filed against DexCom, Inc. for alleged misrepresentations regarding the accuracy and functionality of its Dexcom G7 continuous glucose monitoring system, impacting investors who purchased shares between January 8, 2024, and September 17, 2025 [4][5]. Group 1 - The lawsuit was initiated in the United States District Court for the Southern District of New York on behalf of investors who acquired DexCom securities during the specified period [4]. - Allegations include that the company and certain senior officers made false statements about the device's reliability and enhancements, as well as the expansion of manufacturing capabilities [5]. - Investors interested in participating as lead plaintiffs must file by December 26, 2025, although participation in any recovery does not require serving as lead plaintiff [6]. Group 2 - Bernstein Liebhard LLP, the law firm handling the case, has a history of recovering over $3.5 billion for clients and has been recognized for its litigation success [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities between July 26, 2024, and September 17, 2025, of the December 29, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To join the class action, investors can visit the provided link or contact the law firm for more information [3][6] - A lead plaintiff must file a motion with the Court by December 29, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4] Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5] - Defendants allegedly overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues, leading to increased regulatory scrutiny and potential legal repercussions [5] - The lawsuit claims that the public statements made by the defendants were materially false and misleading, resulting in investor damages when the true information became public [5]

Core Points - A class action securities lawsuit has been filed against DexCom, Inc. for alleged securities fraud affecting investors between January 8, 2024, and September 17, 2025 [1] Group 1: Allegations - The lawsuit claims that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, without FDA approval [2] - These design changes allegedly made the G6 and G7 less reliable, posing a material health risk to users who depend on these devices for accurate glucose readings [2] - The enhancements to the G7's reliability, accuracy, and functionality were reportedly overstated by the defendants [2] - The true scope and severity of the issues with the G7 devices were downplayed, increasing the risk of regulatory scrutiny and potential legal, reputational, and financial harm to DexCom [2] - Public statements made by the defendants were claimed to be materially false and misleading throughout the relevant period [2] Group 2: Legal Process - Investors who suffered losses in DexCom during the specified timeframe have until December 26, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought DexCom securities between July 26, 2024, and September 17, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the lead plaintiff deadline of December 29, 2025 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that DexCom's public statements regarding the reliability and functionality of these devices were materially false and misleading, leading to increased regulatory scrutiny and potential financial harm [5].

Core Viewpoint - Rosen Law Firm is reminding investors of DexCom, Inc. about an important deadline related to a securities class action lawsuit, encouraging them to secure legal counsel before December 29, 2025 [2][4]. Group 1: Class Action Details - The class action pertains to investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, inclusive [2]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - To participate in the class action, investors must act before the lead plaintiff deadline of December 29, 2025 [4]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [6]. - It is claimed that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues related to the devices [6]. - The allegations suggest that these actions exposed DexCom to increased regulatory scrutiny and potential legal and financial repercussions [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [5]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions of dollars for investors [5]. - In 2019, the firm secured over $438 million for investors, highlighting its effectiveness in representing clients [5].

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified class period [1][2]. Allegations Against DexCom - Defendants allegedly made false and misleading statements regarding unauthorized design changes to the G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [2]. - The enhancements claimed for the G7 device were reportedly overstated, and the company downplayed the severity of issues related to the adulterated devices [2]. - These actions have led to increased regulatory scrutiny and potential legal, reputational, and financial harm for DexCom [2]. Lead Plaintiff Process - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiff representatives in the class action, which involves directing the litigation on behalf of all class members [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial interest in the case [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the DexCom securities is from July 26, 2024, to September 17, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - The deadline to move the Court to serve as lead plaintiff is December 29, 2025 [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability [4] - The changes presented a material health risk to users relying on these devices for accurate glucose readings [4] - Defendants allegedly downplayed the severity of the issues, leading to increased regulatory scrutiny and potential legal and financial harm [4]

Core Viewpoint - The Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a securities class action related to misleading statements made by the company during the class period from July 26, 2024, to September 17, 2025 [1][2]. Summary by Sections Class Action Details - Investors who purchased DexCom securities during the specified class period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the lead plaintiff deadline of December 29, 2025 [3]. Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that DexCom downplayed the severity of these issues, leading to increased regulatory scrutiny and potential legal repercussions [5].